SCHEMBL21914746

SCHEMBL21914746

Cc1csc(NC=S)c1C(=O)c1ccc(Cl)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.41
LMNA P02545 4/20 0.39
POLB P06746 2/20 0.39
GAA P10253 1/20 0.39
PKM P14618 1/20 0.39
ALDH1A1 P00352 4/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
KMT2A Q03164 3/20 0.38
HTT P42858 2/20 0.38
HPGD P15428 2/20 0.38
MEN1 O00255 2/20 0.38
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
KDM4E B2RXH2 1/20 0.37
TLR7 Q9NYK1 1/20 0.37
SRD5A2 P31213 1/20 0.37
MAPK1 P28482 1/20 0.37
RAB9A P51151 2/20 0.36
ANO1 Q5XXA6 1/20 0.36
CES2 O00748 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23320326 0.78 ALDH1A1 (0.56) MAPTLMNAGAAALDH1A1SMN1; SMN2
SCHEMBL19986219 0.76 MAPT (0.46) MAPTLMNAPOLBGAAPKM
SCHEMBL19973041 0.75 MAPT (0.46) MAPTLMNAPOLBGAAPKM
SCHEMBL19973040 0.75 MAPT (0.46) MAPTLMNAPOLBGAAPKM
SCHEMBL23320127 0.74 RAB9A (0.55) MAPTLMNAGAAALDH1A1SMN1; SMN2
SCHEMBL23319960 0.74 ALDH1A1 (0.63) MAPTLMNAPOLBGAAALDH1A1
SCHEMBL1497728 0.73 ADORA1 (0.54) KMT2AHTTHPGDMEN1SRD5A2
SCHEMBL20456588 0.73 MAPT (0.47) MAPTLMNAALDH1A1SMN1; SMN2KMT2A
SCHEMBL19973045 0.73 MAPT (0.47) MAPTLMNAALDH1A1SMN1; SMN2KMT2A
SCHEMBL20819238 0.70 MAPT (0.45) MAPTLMNAPOLBPKMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11186588-B2 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative AYUMI PHARMACEUTICAL CORPORATION (JP) 2021-11-30 US disclosed
US-20210130367-A1 6H-THIENO[2,3-e][1,2,4]TRIAZOLO[3,4-c][1,2,4]TRIAZEPINE DERIVATIVE AYUMI PHARMACEUTICAL CORPORATION (JP) 2021-05-06 US disclosed
EP-3640253-A1 6H-THIENO[2,3-E][1,2,4]TRIAZOLO[3,4-C][1,2,4]TRIAZEPINE DERIVATIVE AYUMI Pharmaceutical Corporation (JP) 2020-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210130367-A1 6H-THIENO[2,3-e][1,2,4]TRIAZOLO[3,4-c][1,2,4]TRIAZEPINE DERIVATIVE BRD4, BRD3, BRD2 MAPT 1675/4885LMNA 2211/4885POLB 1559/4885
US-11186588-B2 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative BRD4, BRD3, BRD2 MAPT 1675/4885LMNA 2211/4885POLB 1559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.